DCR-PDL1 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called DCR-PDL1 to assess its safety and behavior in the body. It targets adults with solid tumors or non-Hodgkin's lymphoma that have not responded to standard treatments or for whom no standard treatments exist. Participants will receive the medication through a series of IV doses, with each group trying a different dose level to determine the safest and most effective amount. This trial may suit those whose cancer has worsened despite treatment or cannot be treated with surgery. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that DCR-PDL1 is likely to be safe for humans?
Research shows that treatments targeting PD-L1, such as DCR-PDL1, are usually well-tolerated. Studies with similar PD-1 and PD-L1 inhibitors have reported few side effects, with serious side effects being rare. While these treatments are mostly safe, some patients might still experience mild side effects, including tiredness, skin reactions, or flu-like symptoms. When used for other conditions, these treatments generally support their safety for new uses. Always consult a doctor about specific risks and benefits before joining a trial.12345
Why do researchers think this study treatment might be promising?
Most treatments for cancer focus on targeting tumor cells directly or boosting the immune system to attack them. DCR-PDL1 is unique because it uses an innovative mechanism to silence the PD-L1 protein, which often helps cancer cells evade the immune system. By targeting PD-L1, this treatment could potentially enhance the body's natural ability to fight cancer more effectively than existing immunotherapies. Researchers are excited about DCR-PDL1 because this approach might offer a new way to overcome resistance seen with current therapies, potentially leading to better outcomes for patients.
What evidence suggests that DCR-PDL1 might be an effective treatment for cancer?
Research has shown that PD-1 and PD-L1 inhibitors hold promise in cancer treatment. These treatments can extend the time patients live without their cancer worsening. For instance, patients using similar PD-1 inhibitors lived about 11.5 months without cancer progression, compared to just 2.9 months for those not using these inhibitors. Additionally, about 23-28% of patients experienced a partial or full reduction in tumor size with these treatments. This trial will evaluate DCR-PDL1, which functions similarly, to assess its potential effectiveness in treating solid tumors.12678
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for adults with solid tumors. Participants will be placed into one of four groups to receive increasing doses of DCR-PDL1, given through the veins. Specific eligibility details are not provided, but typically include factors like type and stage of tumor, previous treatments, and overall health.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple IV doses of DCR-PDL1 during each treatment cycle in one of 4 ascending-dose cohorts
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DCR-PDL1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Lead Sponsor